



May 9, 2022

The Honorable Jason E. Kearns
Chairman
U.S. International Trade Commission
500 E Street, SW
Washington, DC 20436

Re: Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same, Inv. No. 337-TA-1238

Dear Chairman Kearns and Commissioners,

I respectfully submit these comments in support of the remedies sought by Complainant Ventria Bioscience, Inc. in the above-referenced proceeding. Ventria is an important member of our life science community in Colorado and has made major scientific innovations that are valuable to the U.S. economy and society at-large.

Ventria (which also operates as InVitria) has invested tens of millions of dollars to develop and commercialize its novel recombinant protein technology. Ventria’s groundbreaking platform enables the production of important mammalian proteins (such as recombinant albumin, rHSA) at a commercial scale, without the use of blood or animal-origin components. This is a significant step forward to help customers eliminate the risk of transmitting blood-borne or animal-origin adventitious pathogens like mad cow disease, HIV or Sars-CoV-2. Ventria has built this business through its entirely U.S.-based research and development investments. Ventria has placed a priority on attracting and hiring talent in the Plains and Mountain West, and it works collaboratively with notable U.S. research institutions and global health initiatives.

It is crucial to protect the U.S. biotechnology industry and innovative American companies, like Ventria, from unfair interference by foreign actors. Ventria has repeatedly faced unlawful competition from China and this is precisely the type of situation that requires the U.S. ITC’s close attention. Exclusion of infringing products from the U.S. market promotes the U.S. public interest.

Without the jurisdiction and remedies afforded by Section 337, it is difficult for companies like Ventria to identify and challenge the importation of infringing products and enforce their intellectual property rights. As such, assuming a violation is upheld by the Commission, I respectfully ask that you afford Ventria the remedial relief it greatly needs.

Thank you for considering this submission. Please feel free to contact me with any questions.

Elyse Blazeovich
President & CEO
Colorado BioScience Association